How to administer zenidatamab for injection (zanidatamab-hrii)-Ziihera

Zenidatamab-hrii for Injection (zanidatamab-hrii)-Ziihera is designed for the treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) who have tested positive for HER2 (IHC 3+) on an FDA-approved test. When using this drug, certain medication methods and procedures must be followed to ensure the effectiveness and safety of the treatment.

When selecting patients, their tumor specimens should be confirmed to be HER2-positive (IHC 3+) using an FDA-approved test. This process is critical to ensuring patients are suitable for treatment with Ziihera. Patients with unresectable or metastatic biliary tract cancer are the main candidates for this drug, and only patients who meet these conditions can carry out subsequent treatment.

Before the official infusion of zenidatuzumab, in order to reduce possible infusion-related reactions, all patients need to undergo preoperative pretreatment30 to 60 minutes before each dose. Acetaminophen is recommended to relieve possible fever, antihistamines (such as diphenhydramine) can effectively control allergic reactions, and corticosteroids (such as hydrocortisone) can help reduce inflammatory reactions. These pretreatment measures can significantly improve patient tolerance and reduce the incidence of adverse reactions.

In terms of dosage, the recommended dose of zenidatuzumab for injection is 20 mg per kilogram of body weight, administered by intravenous infusion once every two weeks. Treatment should be continued until disease progression or unacceptable toxicity occurs. If a patient misses a scheduled dose, the dose should be taken as soon as feasible rather than waiting for the next scheduled dose. This is important because keeping two weeks between doses maximizes the effectiveness of the drug.

Dose adjustment is one of the key steps in individualized treatment. Based on patient tolerance and safety, the dose may be reduced to 15 mg/kg if necessary. If the patient is still unable to tolerate a dose of 15 mg/kg, permanent discontinuation of the drug should be considered. Such a dose adjustment mechanism can not only protect the patient's health, but also flexibly respond to different clinical situations during treatment.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae5d9425-fae5-4541-a158-150998343348##